Status:
COMPLETED
Clinical Relevance of DNMT and HDAC Gene SNP on the Response to Decitabine Therapy for Myelodysplastic Syndrome
Lead Sponsor:
Samsung Medical Center
Conditions:
Myelodysplastic Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
Recent investigations have demonstrated that DNMT gene polymorphisms can contribute to the inter-individual variants in DNMT expression. Accordingly, we hypothesized that the DNMT and HDAC genes SNPs ...
Detailed Description
This study will include the patients who signed the subject informed consent form among the patients with MDS who were chosen to be treated with Decitabine (Part I), plus additional 140 MDS patients a...
Eligibility Criteria
Inclusion
- Decitabine treatment group
- Male and female aged 18 years or older.
- The patients diagnosed with (primary or secondary) MDS
- Patients with an IPSS score of ≥ Int-1
- Patients treated with Decitabine at least 1 cycles.
- Signed and dated informed consent before the start of genetic study using genomic DNA derived from blood sample.
- Historical control group
- Male and female aged 18 years or older.
- The patients diagnosed with (primary or secondary) MDS
Exclusion
- Patients diagnosed with acute myelogenous leukemia (AML, bone marrow stem cell counts exceeding 20%) or other progressive malignant diseases.
- Diagnosis of chronic myelomonocytic leukemia (CMML) or MDS/MPD excluded.
Key Trial Info
Start Date :
September 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 1 2010
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT04515914
Start Date
September 1 2009
End Date
November 1 2010
Last Update
August 17 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, South Korea, 135-710